Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis.
Expert opinion on biological therapy（2023）
Abstract
NCT04930042; EudraCT Number: 2020 -004,493-22.
MoreTranslated text
Key words
AVT04, ustekinumab, biosimilar, moderate-to-severe chronic plaque psoriasis, therapeutic equivalence
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined